Meetings to be held July 28-August 1 hosted by Oppenheimer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma’s Promising Clinical Trials and Strategic Plans Drive Buy Rating with $40 Price Target
- Buy Rating for ArriVent BioPharma: Promising Potential of Lead Candidate and Solid Financial Position
- ArriVent BioPharma Announces Phase 3 Trial Data Release
- ArriVent Biopharma announces data from its FURVENT Phase 3 study
- ArriVent BioPharma, Inc.: Promising Developments and Strategic Advancements Drive Buy Rating